Ying Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Xia has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Boyang Bian
Biogen, Cambridge, USA
1 shared publication Chenghao Zheng
School of Medicine, Shanghai JiaoTong University, Shanghai, PR China
1 shared publicationChristina M. L. Kelton
Division of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy, and Carl H. Lindner College of Business, University of Cincinnati, Cincinnati, OH, USA
1 shared publication- Jeff Jianfei Guo
Univ Cincinnati, Acad Hlth Ctr, James L Winkle Coll Pharm, Cincinnati, OH USA
1 shared publication - Jun Liu
Southern Med Univ, Dept Urol, Zhujiang Hosp, Guangzhou 510280, Peoples R China
1 shared publication Liang Xue
College of Medicine, State University of New York at Buffalo, Buffalo, NY, USA
1 shared publication
Latest Publications
- 19 February 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 102 (6) , 589-601
MicroRNA-483-5p accentuates cisplatin-induced acute kidney injury by targeting GPX3
- 19 February 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 102 (6) , 589-601
MicroRNA-483-5p accentuates cisplatin-induced acute kidney injury by targeting GPX3
- Open Access
- 20 September 2013
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 4 (6) , 254-263
Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use of LABAs has raised safety concerns, especially the potential for severe asthma exacerbations (SAEs) resulting in hospitalizations or even death. Meanwhile, the use of inhaled corticosteroids (ICSs), a cornerstone in the treatment of mild-to-severe persistent asthma, has been associated with growth suppression in children. The purpose of this review was to identify and discuss the major published safety studies surrounding LABA, ICS, and combined LABA/ICS usage in children. By way of a critical search for influential published clinical trials, meta-analyses, and observational studies, six studies relevant to the safety of LABA monotherapy, seven studies relevant to ICS monotherapy, and four studies on the subject of LABA/ICS combination usage were identified and reviewed. Based on the reviewed literature, the controversy surrounding these anti-asthma medications was clearly exposed. On the one hand, there is some evidence that LABA monotherapy may be associated with SAEs and asthma-related death, while ICS monotherapy may be associated with a higher risk of growth suppression. On the other hand, the concurrent use of a LABA with an ICS has been associated with positive outcomes including symptom reduction and reduced rate and severity of exacerbations. Further clinical research is warranted and has been called for by the US Food and Drug Administration.
- 20 September 2013
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 4 (6) , 254-263
Open AccessSafety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use of LABAs has raised safety concerns, especially the potential for severe asthma exacerbations (SAEs) resulting in hospitalizations or even death. Meanwhile, the use of inhaled corticosteroids (ICSs), a cornerstone in the treatment of mild-to-severe persistent asthma, has been associated with growth suppression in children. The purpose of this review was to identify and discuss the major published safety studies surrounding LABA, ICS, and combined LABA/ICS usage in children. By way of a critical search for influential published clinical trials, meta-analyses, and observational studies, six studies relevant to the safety of LABA monotherapy, seven studies relevant to ICS monotherapy, and four studies on the subject of LABA/ICS combination usage were identified and reviewed. Based on the reviewed literature, the controversy surrounding these anti-asthma medications was clearly exposed. On the one hand, there is some evidence that LABA monotherapy may be associated with SAEs and asthma-related death, while ICS monotherapy may be associated with a higher risk of growth suppression. On the other hand, the concurrent use of a LABA with an ICS has been associated with positive outcomes including symptom reduction and reduced rate and severity of exacerbations. Further clinical research is warranted and has been called for by the US Food and Drug Administration.